BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ASRT: Updated Q4 Results Puts 2023 in Focus

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>ASRT could significantly benefit from a new guideline set by American Society for Gastrointestinal Endoscopy ("ASEG") this week related to the use of indomethacin (Indocin) post ERCP surgery.</li>
<li>Indocin is ASRT's largest source of revenue and nearly all the revenue from off-line use related to post ERCP surgery.</li>
<li>We updated our earnings model when ASRT issued preliminary fourth quarter results. We believe the ASEG guidance could lead to accelerated market expansion in coming months</li>
</ul>


ASRT could significantly benefit from a new guideline set by American Society for Gastrointestinal Endoscopy ("ASEG") this week related to the use of indomethacin (Indocin) post ERCP surgery.
Indocin is ASRT's largest source of revenue and nearly all the revenue from off-line use related to post ERCP surgery.
We updated our earnings model when ASRT issued preliminary fourth quarter results. We believe the ASEG guidance could lead to accelerated market expansion in coming months


ASRT: ASEG Guideline a Significant Positive, PT to $8

Assertio Holdings

ASRT: ASEG Guideline a Significant Positive, PT to $8